Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Trial Profile

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs PSMA 617 (Primary) ; Antineoplastics
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms VISION
  • Sponsors Endocyte
  • Most Recent Events

    • 10 Sep 2018 According to an Endocyte media release, regardless of the outcome of the rPFS assessment, Endocyte intends to continue to follow patients in the VISION trial in order to assess the final OS alternative primary endpoint.
    • 10 Sep 2018 Under the updated protocol, the two interim assessments previously planned at 50% and 70% of OS events will be replaced with a single assessment of rPFS, according to an Endocyte media release. The rPFS analysis is expected in late 2019, approximately one year ahead of final OS analysis.
    • 10 Sep 2018 According to an Endocyte media release, the company announced that following a meeting with the FDA it has been determined that radiographic progression-free survival (rPFS) is an appropriate alternative primary efficacy endpoint in this trial to support the submission of a New Drug Application (NDA) for full FDA approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top